Literature DB >> 11191884

Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) gene in patients with fish-odour syndrome.

C T Dolphin1, A Janmohamed, R L Smith, E A Shephard, I R Phillips.   

Abstract

Fish-odour syndrome is a highly unpleasant disorder of hepatic trimethylamine (TMA) metabolism characterized by a body odour reminiscent of rotting fish, due to excessive excretion of the malodorous free amine. Although fish-odour syndrome may exhibit as sequelae with other conditions (e.g. liver dysfunction), many patients exhibit an inherited, more persistent form of the disease. Ordinarily, dietary-derived TMA is oxidized to the nonodorous N-oxide by hepatic flavin-containing monooxygenase 3 (FMO3). Our previous demonstration that a mutation, P153L (C to T), in the FMO3 gene segregated with the disorder and inactivated the enzyme confirmed that defects in FMO3 underlie the inherited form of fish-odour syndrome. We have investigated the genetic basis of the disorder in two further affected pedigrees and report that the three propositi are all compound heterozygotes for causative mutations of FMO3. Two of these individuals possess the P153L (C to T) mutation and a novel mutation, N61S (A to G). The third is heterozygous for novel, M4341 (G to A), and previously reported, R492W (C to T), mutations. Functional characterization of the S61, 1434 and W492 variants, via baculovirus-mediated expression in insect cells, confirmed that all three mutations either abolished, or severely attenuated, the capacity of the enzyme to catalyse TMA N-oxidation. Although 1434 and W492 were also incapable of catalysing the S-oxidation of methimazole, S61 was fully active with this sulphur-containing substrate. Since an asparagine is conserved at the equivalent position to N61 of FMO3 in mammalian, yeast and Caenorhabditis elegans FMOs, the characterization of the naturally occurring N61S (A to G) mutation may have identified this asparagine as playing a critical role specifically in FMO-catalysed N-oxidation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11191884     DOI: 10.1097/00008571-200012000-00005

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  13 in total

1.  Clinical utility gene card for: trimethylaminuria.

Authors:  Elizabeth A Shephard; Eileen P Treacy; Ian R Phillips
Journal:  Eur J Hum Genet       Date:  2011-11-30       Impact factor: 4.246

2.  Relationships between flavin-containing mono-oxygenase 3 (FMO3) genotype and trimethylaminuria phenotype in a Japanese population.

Authors:  Makiko Shimizu; Charles K Allerston; Elizabeth A Shephard; Hiroshi Yamazaki; Ian R Phillips
Journal:  Br J Clin Pharmacol       Date:  2014-05       Impact factor: 4.335

3.  Ancestral-sequence reconstruction unveils the structural basis of function in mammalian FMOs.

Authors:  Callum R Nicoll; Gautier Bailleul; Filippo Fiorentini; María Laura Mascotti; Marco W Fraaije; Andrea Mattevi
Journal:  Nat Struct Mol Biol       Date:  2019-12-23       Impact factor: 15.369

Review 4.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

5.  Joint functions of protein residues and NADP(H) in oxygen activation by flavin-containing monooxygenase.

Authors:  Roberto Orru; Daniel E Torres Pazmiño; Marco W Fraaije; Andrea Mattevi
Journal:  J Biol Chem       Date:  2010-08-31       Impact factor: 5.157

6.  Functional characterization of genetic variants of human FMO3 associated with trimethylaminuria.

Authors:  Catherine K Yeung; Elinor T Adman; Allan E Rettie
Journal:  Arch Biochem Biophys       Date:  2007-05-02       Impact factor: 4.013

7.  Clinical utility gene card for: Trimethylaminuria - update 2014.

Authors:  Elizabeth A Shephard; Eileen P Treacy; Ian R Phillips
Journal:  Eur J Hum Genet       Date:  2014-10-22       Impact factor: 4.246

8.  Nicotine-N'-Oxidation by Flavin Monooxygenase Enzymes.

Authors:  Yadira X Perez-Paramo; Gang Chen; Joseph H Ashmore; Christy J W Watson; Shamema Nasrin; Jennifer Adams-Haduch; Renwei Wang; Yu-Tang Gao; Woon-Puay Koh; Jian-Min Yuan; Philip Lazarus
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-10-31       Impact factor: 4.254

Review 9.  Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease.

Authors:  Diede Fennema; Ian R Phillips; Elizabeth A Shephard
Journal:  Drug Metab Dispos       Date:  2016-05-17       Impact factor: 3.922

10.  Inactivation mechanism of N61S mutant of human FMO3 towards trimethylamine.

Authors:  Chongliang Gao; Gianluca Catucci; Silvia Castrignanò; Gianfranco Gilardi; Sheila J Sadeghi
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.